Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Table 1 Baseline demographics and clinical characteristics

Characteristic, n (%)^a	N = 22
Median age, years (range)	61 (23–76)
Sex
Male	9 (41)
Female	13 (59)
Race
Asian	7 (32)
Multiracial	1 (5)
White	14 (64)
ECOG PS
0	12 (55)
1	10 (45)
Thyroid cancer histology
Papillary	15 (68)
Follicular	7 (32)
Treatment-naive^b
Yes	6 (27)
No	16 (73)
Prior lines of therapy for advanced disease
1	7 (32)
2	5 (23)
3	3 (14)
4	1 (5)
Unknown	6 (27)
Select prior therapies^c
Iodine	18 (82)
Sorafenib	7 (32)
Pazopanib	3 (14)
Lenalidomide	2 (9)
Cediranib	2 (9)
Vemurafenib	2 (9)
Sunitinib	2 (9)
Everolimus	2 (9)
Paclitaxel	2 (9)

ECOG PS Eastern Cooperative Oncology Group performance status
^aTotals may equal > 100% because of rounding
^bPatients had received no prior oncologic or biologic drugs but may have received iodine radiotherapy or surgery
^cPatients may have received more than 1 prior treatment listed

ISSN: 1471-2407